Recent memos allegedly leaked from the Colombian Embassy in Washington describe intense pressure by the pharmaceutical industry to discourage Colombia's efforts to half the local price of Novartis' Gleevec, one of the leading medications used to treat Chronic Myelogenous Leukemia (CML).
Tamara Jacobs knows what she's talking about when it comes to moving ahead in the business world. When Fortune 500 companies like Pfizer, Johnson & Johnson, Bayer, Merck, Novartis, Revlon, and others need advice with their branding and image, they call Tamara.
The pharmaceutical sector is still struggling to find an operating model that will work in the 21st century. The shocking news of GlaxoSmithKline's sale of its cancer-drug business to Novartis -- and the many recent huge deals like it -- are the most recent evidence.
The costs of protectionism can be large, as economists frequently point out when discussing 20 percent tariffs in steel. For some reason they become strangely silent when it comes to patent protection that raise the price of drugs by 1,000 percent.